RxDoctor Payments Data

Britni Turkenburg

Physician Assistant · Coeur D Alene, IDNPI 1851869200

Payments from drug & device makers

$2,864in general payments, 2019–2025

Across 78 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$1K
  • AbbVie$596
  • Johnson & Johnson$290
  • Bristol Myers Squibb$151
  • Takeda Pharmaceuticals U.S.A., Inc.$104
  • Phathom Pharmaceuticals, Inc.$86
  • plus $493 from 11 others

What the payments were for

  • Food & beverage$2,71395%
  • Education$1515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,864 in reported general payments places this provider in the 85th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$27,139
Medicare patients
244
Services billed
354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin48$155,182
ZenpepLipase/Protease/Amylase22$57,150
LinzessLinaclotide64$51,813
MovantikNaloxegol Oxalate23$13,928
MotegrityPrucalopride Succinate22$12,758
CholestyramineCholestyramine (With Sugar)27$2,017
Pantoprazole Sodium73$1,405
Omeprazole98$1,177
Lubiprostone11$1,079
Budesonide DrBudesonide11$752
Metoclopramide Hcl15$260
Famotidine17$176
Nortriptyline Hcl19$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$86$155,18248 claims
AbbVieLinzess$596$51,81364 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$104$12,75822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →